Palatin Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTN research report →
Range $47.5 – $60
Price Chart
About the company
Palatin Technologies, Inc. , a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
- CEO
- Carl Spana
- IPO
- 1997
- Employees
- 25
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on PTN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.16M
- P/E
- -0.43
- PEG
- 0.00
- P/S
- 1.87
- P/B
- 9.54
- EV/EBITDA
- -0.29
- Div Yield
- 0.00%
- Gross Margin
- 98.97%
- Op Margin
- -392.22%
- Net Margin
- -385.44%
- ROE
- -235.46%
- ROIC
- -843.30%
Latest fiscal year · YoY change
- Revenue
- $13.19M+0.0%
- Gross Profit
- $13.12M+0.0%
- Op Income
- $-8,668,288
- Net Income
- $-8,377,895+51.6%
- EPS
- $-2.96+90.8%
- OCF Growth
- +36.5%
- FCF Growth
- +36.2%
- 52W High
- $31.00
- 52W Low
- $4.51
- 50D MA
- $7.64
- 200D MA
- $13.31
- Beta
- -0.07
- RSI (14)
- 35
- Avg Volume
- 71.68K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Palatin said it is doubling down on next-generation MC4R obesity programs, while Q1 revenue fell sharply year over year and cash remained tight at $3.7 million.· November 17, 2026
- Q1 collaboration and license revenue was about $362,000 versus about $8.8 million a year ago, reflecting the prior-year Boehringer upfront milestone.
- R&D rose to about $3.4 million, with MC4R obesity program spending increasing to about $2.1 million from about $1 million.
- The company reported a net loss of about $5.1 million, or $1.29 per share, and ended the quarter with about $3.7 million in cash and equivalents.
- Management said the lead lipidated peptide is still targeted for a Phase I study in the first half of calendar 2027, with initial data expected in the second half of 2027.
- Palatin said it is actively evaluating financing alternatives, including public and private equity, while continuing strategic collaborations.
For fiscal Q1 2027, Palatin recognized about $362,000 in collaboration and license revenue, down from about $8.8 million in the prior-year period. R&D expense was about $3.4 million versus about $2.5 million a year ago, and G&A was about $2.1 million versus about $1.7 million. The company reported a net loss of about $5.1 million, or $1.29 per basic and diluted share, and net cash used in operating activities was about $3.7 million versus about $1.6 million last year. Cash and cash equivalents were about $3.7 million at September 30, 2026. Management’s roadmap remains to initiate a Phase I single/multiple ascending dose study for the lead lipidated MC4R peptide in the first half of calendar 2027, with initial data in the second half of 2027; the oral small molecule and oral peptide programs are expected to start about two quarters later, with data in the first half of calendar 2028.
Carl Spana emphasized that MC4R is now a clinically and commercially validated obesity mechanism, and said Palatin wants to build “better medicines” around it. He repeatedly framed the company’s strategy as differentiation through receptor selectivity, especially reducing MC1R activity to avoid hyperpigmentation, while pursuing multiple formats including lipidated peptides, non-lipidated peptides, oral small molecules, and oral peptide approaches. His tone was confident and upbeat, but grounded in the view that the company still needs to prove the programs in humans.
Steve Wills focused on the financial picture and capital strategy. He highlighted the quarter’s approximately $362,000 of revenue, $3.4 million of R&D, $2.1 million of G&A, and $3.7 million cash balance, then said the company will need additional capital to move into clinical development. He said Palatin is evaluating public and private equity financing as well as strategic collaborations, while continuing to manage spending carefully and prioritize MC4R obesity programs.
Analysts pressed on what the increased industry attention to MC4R means for Palatin, including comparisons with Rhythm and interest from large pharma. Management said the rising interest is a positive for the field and argued Palatin is differentiated by its peptide know-how, lipidation expertise, and oral delivery work. Questions also focused on hyperpigmentation, blood pressure/cardiovascular risk, and timelines; management said a 28-day study should be enough to reveal MC1R-driven pigmentation effects, and that blood pressure and rhythm will be monitored through tox and in the clinic. On financing, management said interest has been “significantly greater” in recent months and that the BI collaboration has already brought in about $10 million since August 2025, with more milestones possible later.
The call showed a company leaning into a mechanism management believes is now validated and attracting broader industry interest. Palatin is advancing multiple MC4R shots on goal, with a lead lipidated peptide, oral small molecule, and oral peptide all moving toward clinic, while management believes its compounds may offer better selectivity and less hyperpigmentation than existing approaches.
Palatin remains a development-stage company with limited cash, having just $3.7 million on hand at quarter-end and a stated need for additional financing. Revenue was heavily dependent on collaboration timing, and the core obesity programs still need to clear IND-enabling work, human safety, tolerability, blood pressure, and pigmentation readouts before any clinical validation.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.8%
- Shares Outstanding
- 1.78M
- Float Shares
- 1.56M
of shares held by institutions
25 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Driehaus Capital Management LLC | 166.71K | 0 |
| Jupiter Topco LLC | 140.00K | ▲ 140.00K |
| Janus Henderson Group Ltd. | 140.00K | 0 |
| Logos Global Management LP | 130.00K | ▼ 10.00K |
| Ra Capital Management, L.P. | 62.12K | ▼ 7.88K |
| Balyasny Asset Management L.P. | 41.11K | ▼ 59 |
| Vanguard Group Inc | 29.00K | ▲ 29.00K |
| Morgan Stanley | 27.27K | 0 |
| Geode Capital Management, LLC | 20.62K | ▲ 1.24K |
| Opaleye Management Inc. | 20.50K | ▲ 20.50K |
| Vanguard Capital Management LLC | 18.91K | 0 |
| Jane Street Group, LLC | 17.00K | ▲ 17.00K |
Held by 9 ETFs
Biggest fund positions in PTN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 3, 26 | Morris Arlene | other | 2,400 |
| Aug 3, 26 | DUNTON ALAN W | other | 2,200 |
| Aug 3, 26 | PRENDERGAST JOHN K A | other | 2,900 |
| Jul 15, 26 | SPANA CARL | other | 33 |
| Jul 15, 26 | SPANA CARL | other | 119 |
| Jul 15, 26 | SPANA CARL | other | 142 |
| Jul 15, 26 | WILLS STEPHEN T | other | 22 |
| Jul 15, 26 | WILLS STEPHEN T | other | 79 |
| Jul 15, 26 | WILLS STEPHEN T | other | 94 |
| Dec 30, 25 | WILLS STEPHEN T | other | 26 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PTN coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PTN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Palatin Technologies, Inc. (PTN) Q1 2027 Earnings Call Transcript
seekingalpha.com · Nov 17
Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
prnewswire.com · Nov 17
Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026
prnewswire.com · Nov 16
Palatin to Report First Quarter Fiscal Year 2027 Results
prnewswire.com · Nov 13
This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
benzinga.com · Nov 6
What Palatin Technologies (PTN) Said on Its Q4 Earnings Call
defenseworld.net · Sep 29
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
seekingalpha.com · Sep 28
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
gurufocus.com · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
